# Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)

> **NCT00606580** · PHASE3 · COMPLETED · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 375 (actual)

## Conditions studied

- Cutaneous Leishmaniasis

## Interventions

- **DRUG:** WR 279,396 topical cream
- **DRUG:** Paromomycin Alone topical cream
- **DRUG:** Vehicle placebo cream

## Key facts

- **NCT ID:** NCT00606580
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 375 (ACTUAL)
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00606580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00606580, "Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00606580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*